If You Invested $10,000 in Novavax in 2020, This Is How Much You Would Have Today

3
1
Favorite

If You Invested $10,000 in Novavax in 2020, This Is How Much You Would Have Today

Motley Fool2021-12-30

Novavax (NASDAQ:NVAX) has been a volatile stock over the past few years. From optimism around its COVID-19 vaccine to concerns about delays, it has sent its investors on a roller-coaster ride. Early ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

gfy
·2021-12-31
Nice analysis! Unfortunately all of us can only wish we had a crystal ball, right?
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2195932414?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-12-30 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2195932414","market":"us","top_or_hot":-1,"title":"If You Invested $10,000 in Novavax in 2020, This Is How Much You Would Have Today","media":"Motley Fool","content":"<div>\n<p>Novavax (NASDAQ:NVAX) has been a volatile stock over the past few years. From optimism around its COVID-19 vaccine to concerns about delays, it has sent its investors on a roller-coaster ride. Early ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/30/if-you-invested-10000-in-novavax-in-2020-this-is-h/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If You Invested $10,000 in Novavax in 2020, This Is How Much You Would Have Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf You Invested $10,000 in Novavax in 2020, This Is How Much You Would Have Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 00:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/30/if-you-invested-10000-in-novavax-in-2020-this-is-h/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) has been a volatile stock over the past few years. From optimism around its COVID-19 vaccine to concerns about delays, it has sent its investors on a roller-coaster ride. Early ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/30/if-you-invested-10000-in-novavax-in-2020-this-is-h/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://www.fool.com/investing/2021/12/30/if-you-invested-10000-in-novavax-in-2020-this-is-h/","article_id":"2195932414","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2195932414","pubTimestamp":1640793600,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Your returns could range between a loss and more than 3,000% depending on which month you invested in.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BK4568":"美国抗疫概念","BK4139":"生物科技"},"translate_title":"如果你在2020年在诺瓦瓦克斯医药投资1万美元，这就是你今天的收入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1},"content_text":"Novavax (NASDAQ:NVAX) has been a volatile stock over the past few years. From optimism around its COVID-19 vaccine to concerns about delays, it has sent its investors on a roller-coaster ride. Early investors are sitting on some incredible returns right now, but those who bought early on this year when the stock was trading at more than $300 have incurred steep losses.\nI'll look back at how you would have done in 2020 if you had bought at different months, and how early you would have needed to get in on the stock to earn a great return. And, most importantly, I'll assess whether the stock worth buying today.\n\nImage source: Getty Images\n\nHow early would have been early enough in 2020?\nHere's a look at Novavax's share price at the start of each month of 2020, how many shares you could have bought with a $10,000 investment, and what the value of it would be today. \n\n\n\nMonth\nClosing Price\nShares Bought\nApproximate Value Today\nReturn\n\n\n\n\nJanuary\n$4.49\n2,227.2\n $351,448\n3,414%\n\n\nFebruary\n$6.81\n1,468.4\n $231,718\n2,217%\n\n\nMarch\n$12.02\n831.9\n $131,281\n1,213%\n\n\nApril\n$14.03\n712.8\n $112,473\n1,025%\n\n\nMay\n$17.33\n577.0\n $91,056\n811%\n\n\nJune\n$52.82\n189.3\n $29,875\n199%\n\n\nJuly\n$79.70\n125.5\n $19,799\n98%\n\n\nAugust\n$155.87\n64.2\n $10,124\n1%\n\n\nSeptember\n$105.08\n95.2\n $15,017\n50%\n\n\nOctober\n$104.90\n95.3\n $15,043\n50%\n\n\nNovember\n$82.40\n121.4\n $19,150\n92%\n\n\nDecember\n$123.47\n81.0\n $12,780\n28%\n\n\n\nData source: Yahoo! Finance.\nInvesting at the start of January would have netted the best return, at a whopping 3,414%. It was late February that the healthcare company announced it was advancing development of its COVID-19 vaccine and that phase 1 trials would commence in the coming months. If you had the foresight to bet on the company at that point, it would have been a tremendous gamble; it wasn't until March that the World Health Organization (WHO) even declared the coronavirus a pandemic. The company was also coming off a year in which it generated just $19 million in revenue (mainly through grants and government contracts) and incurred a loss of $133 million.\nApril presented a more realistic time when the risk-reward ratio became more tenable. At that point, the pandemic was here and Novavax had announced the previous month that it would be receiving $4 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to help with the development of the vaccine. In May, CEPI would add another $384 million to that funding. Before the end of the month, the company enrolled its first participants in its phase 1/2 trial. By the start of June, shares were already up over $50. If you waited until then, your investment would have tripled in value.\nAnd if you waited until December, the stock would be up to $123. Later in the month, the U.S. Food and Drug Administration would issue Emergency Use Authorizations (EUAs) for vaccines from Pfizer and Moderna. The authorization for Johnson & Johnson's vaccine would come in February 2021. \nIs Novavax a good buy today?\nIt has been more than a year since the EUAs came in for Moderna and Pfizer's vaccines. More than 60% of the U.S. population is fully vaccinated and many people are on their way to receiving their booster shots. Novavax could apply for an EUA any day now, and investors may be getting unnerved by the lack of progress and constant delays. \nBut even if it doesn't obtain an EUA in the U.S., there's arguably much more of a need to fill in other parts of the world, especially in countries where vaccination rates are significantly lower. The downside is that Novavax might not fetch as high a price for its vaccine, but it would still generate revenue nonetheless. In November, Novavax received EUAs from the Philippines and Indonesia for its vaccine, and it has applied for approvals in other countries as well. On Dec. 17, the World Health Organization added the vaccine to its Emergency Use Listing, potentially paving the way for Novavax's vaccine to get exported to even more countries.\nIt's safe to say that Novavax will generate COVID-19-related revenue, but whether it will be enough to support its current valuation is the bigger question at this point. At a forward price-to-sales (P/S) multiple of more than eight, it's priced higher than the other vaccine makers mentioned earlier:\n\nNVAX PS Ratio (Forward) data by YCharts\nNovavax has taken a long time to get to where it is today, which is well behind the leaders in the COVID-19 vaccine market at this point. And based on that track record, I wouldn't take a chance on a stock that has created a bit of reputation for delays and disappointing investors. At this stage, there may be more risk than there is reward, and that's why I'd avoid Novavax stock for now.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9003897561,"gmtCreate":1640920473781,"gmtModify":1676533555373,"author":{"id":"3585907907201082","authorId":"3585907907201082","name":"gfy","avatar":"https://static.tigerbbs.com/5a74f7299f0be4bc2af3a318ef1e85c4","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3585907907201082","idStr":"3585907907201082"},"htmlText":"Nice analysis! Unfortunately all of us can only wish we had a crystal ball, right?","listText":"Nice analysis! Unfortunately all of us can only wish we had a crystal ball, right?","text":"Nice analysis! Unfortunately all of us can only wish we had a crystal ball, right?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003897561","repostId":2195932414,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}